Abstract:
A simple, accurate, precise and stability indicating RP-HPLC method was developed
and validated for simultaneous estimation of cefixime trihydrate and moxifloxacin
hydrochloride in bulk and tablet dosage form. The RP-HPLC method has shown
adequate separation for cefixime trihydrate and moxifloxacin hydrochloride from its
degradation products. The separation was achieved on a thermoscientific BDS
HYPERSIL C18 (250mm X 4.6 mm i.d., 5 μm particle size) column with an isocratic
mixture of Acetonitrile: 10 mM tetrabutyl ammonium hydrogen sulphate(TBAHS) +
tetrabutyl ammonium bromide(TBAB) buffer pH 3.0 adjusted with glacial
orthophosphoric acid in the ratio of 20:80 v/v. The mobile phase at a flow rate of 1.5
ml/min, injection volume 20μl and wavelength of detection was kept at 280.8 nm. The
retention times for cefixime trihydrate and moxifloxacin hydrochloride were 5.202
±0.1 min and 3.043 ± 0.1 min respectively. Force degradation study was carried out
on combined dosage form as per ICH guidelines and it was exposed to hydrolysis
(acid and base), oxidative, thermal and photo conditions to apply stress. The force
degradation behavior showed that cefixime trihydrate was more prone to degradation
compared to moxifloxacin hydrochloride. The linearity of the developed method was
found in the range of 10-60μg/ml for both cefixime trihydrate and moxifloxacin
hydrochloride. Correlation coefficient was 0.999 for both cefixime trihydrate and moxifloxacin hydrochloride. The limit of detection was 0.929μg/ml and 0.873μg/ml
for moxifloxacin hydrochloride and cefixime trihydrate respectively and the limit of
quantification was 2.816μg/ml and 2.646μg/ml for moxifloxacin hydrochloride and
cefixime trihydrate respectively. Developed stability indicating assay method was
validated as per ICH guidelines for linearity, specificity, accuracy, precision and
robustness for estimation of cefixime trihydrate and moxifloxacin hydrochloride using
synthetically prepared tablet dosage form and results were found to be satisfactory.
